- Email: [email protected]
4717717 Stabilized compositions containing epidermal growth factor
PATENT ABSTRACTS
282
4717569 UNIT DOSAGE FORM OF SPARINGLY SOLUBLE MEDICAMENTS Paul Harrison, John R Langridge, Christopher J Potter, Alnwick, United Kingdom assigned to Sterling Drug Inc Pharmaceutical compositions of a polycyclic medicament having very low solubility in water and aqueous media comprise a plurality of beads, each bead comprising particles of finely divided medicament, which may have a particulate core or filler, bound together by a water soluble binder. 4717713 CONTROLLED RELEASE LIQUID PHARMACEUTICAL Joel L Zatz, David Woodford assigned to Research Corporation A controlled release pharmaceutical composition including a solution or suspension vehicle and a pharmaceutically active agent. The composition is administered to the body in a normally liquid formulation and thereafter forms a semi-solid gel-like matrix in the environment of the stomach thereby effecting controlled release of the pharmaceutically active agent. 4717714 A-51568B ANTIBIOTIC LaVerne Boeck, Gary Marconi, Marvin Hoehn assigned to Eli Lilly and Company The novel glycopeptide antibiotic A-51568B is produced by submerged, aerobic fermentation of Nocardia orientalis N R R L 15232. A-51568B demonstrates antibiotic activity against grampositive bacteria. 4717717 STABILIZED COMPOSITIONS CONTAINING EPIDERMAL GROWTH FACTOR Amy Finkenaur assigned to Ethicon lnc
Medicinal compositions containing epidermal growth factor are stabilized against loss of biological activity in the presence of moisture by including in said compositions a stabilizing amount of water-soluble cellulose polymer, preferably methylcellulose or a hydroxy alkylcellulose such as hydroxypropyl methylcellulose. 4717718 DEVICE FOR THE CONTROLLED DELIVERY OF A BENEFICIAL AGENT James Eckenhoff, Richard Cortese, Felix A Landrau assigned to ALZA Corporation A device for the controlled delivery of a beneficial agent is disclosed. The device comprises (a) a formulation layer and (b) a layer comprising means for pushing the formualtion layer from said device. The formulation layer comprises the beneficial agent avermectin or ivermectin. 4717719 MODIFIED GLUCOSAMINOGLUCANS HAVING ANTITHROMBOTIC ACTIVITY Giancarlo Sportoletti, Piergiuseppe Pagella, Pietro Cremonesi, Milan, Italy assigned to Italfarmaco S p A Pharmaceutical compositions are described which have antithrombotic activity suitable for the prevention and for the therapy of cardiac infarcts, cerebral infarcts and venous thrombosis. They contain as the active component a fraction of heparin which has been modified by nitrogen desulfatation and succinylation, which fraction contains less than 10~ of the N-sulfate groups of the heparin starting material and more than 0.6 succinyl radicals per disaccharide unit. The method of treatment is described. 4717720 BENZONAPHTHALENE DERIVATIVES AND COMPOSITIONS Braham Shroot, Jacques Eustache, Jean-Michel Bernardon, Antibes, France assigned to Centre International de Recherches Dermatologiques (CIRD)
282
4717569 UNIT DOSAGE FORM OF SPARINGLY SOLUBLE MEDICAMENTS Paul Harrison, John R Langridge, Christopher J Potter, Alnwick, United Kingdom assigned to Sterling Drug Inc Pharmaceutical compositions of a polycyclic medicament having very low solubility in water and aqueous media comprise a plurality of beads, each bead comprising particles of finely divided medicament, which may have a particulate core or filler, bound together by a water soluble binder. 4717713 CONTROLLED RELEASE LIQUID PHARMACEUTICAL Joel L Zatz, David Woodford assigned to Research Corporation A controlled release pharmaceutical composition including a solution or suspension vehicle and a pharmaceutically active agent. The composition is administered to the body in a normally liquid formulation and thereafter forms a semi-solid gel-like matrix in the environment of the stomach thereby effecting controlled release of the pharmaceutically active agent. 4717714 A-51568B ANTIBIOTIC LaVerne Boeck, Gary Marconi, Marvin Hoehn assigned to Eli Lilly and Company The novel glycopeptide antibiotic A-51568B is produced by submerged, aerobic fermentation of Nocardia orientalis N R R L 15232. A-51568B demonstrates antibiotic activity against grampositive bacteria. 4717717 STABILIZED COMPOSITIONS CONTAINING EPIDERMAL GROWTH FACTOR Amy Finkenaur assigned to Ethicon lnc
Medicinal compositions containing epidermal growth factor are stabilized against loss of biological activity in the presence of moisture by including in said compositions a stabilizing amount of water-soluble cellulose polymer, preferably methylcellulose or a hydroxy alkylcellulose such as hydroxypropyl methylcellulose. 4717718 DEVICE FOR THE CONTROLLED DELIVERY OF A BENEFICIAL AGENT James Eckenhoff, Richard Cortese, Felix A Landrau assigned to ALZA Corporation A device for the controlled delivery of a beneficial agent is disclosed. The device comprises (a) a formulation layer and (b) a layer comprising means for pushing the formualtion layer from said device. The formulation layer comprises the beneficial agent avermectin or ivermectin. 4717719 MODIFIED GLUCOSAMINOGLUCANS HAVING ANTITHROMBOTIC ACTIVITY Giancarlo Sportoletti, Piergiuseppe Pagella, Pietro Cremonesi, Milan, Italy assigned to Italfarmaco S p A Pharmaceutical compositions are described which have antithrombotic activity suitable for the prevention and for the therapy of cardiac infarcts, cerebral infarcts and venous thrombosis. They contain as the active component a fraction of heparin which has been modified by nitrogen desulfatation and succinylation, which fraction contains less than 10~ of the N-sulfate groups of the heparin starting material and more than 0.6 succinyl radicals per disaccharide unit. The method of treatment is described. 4717720 BENZONAPHTHALENE DERIVATIVES AND COMPOSITIONS Braham Shroot, Jacques Eustache, Jean-Michel Bernardon, Antibes, France assigned to Centre International de Recherches Dermatologiques (CIRD)